Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

Subcutaneous envafolimab monotherapy in patients with advanced defective mismatch repair/microsatellite instability high solid tumors

Abstract Background Monoclonal antibodies targeting programmed death ligand 1 (PD-L1) signaling currently approved for defective mismatch repair (dMMR)/microsatellite instability high (MSI-H) tumors must be delivered by intravenous infusion. Envafolimab, a humanized single-domain anti-PD-L1 antibody...

Full description

Bibliographic Details
Main Authors: Jian Li, Yanhong Deng, Weijie Zhang, Ai-Ping Zhou, Weijian Guo, Jianwei Yang, Ying Yuan, Liangjun Zhu, Shukui Qin, Silong Xiang, Haolan Lu, John Gong, Ting Xu, David Liu, Lin Shen
Format: Article
Language:English
Published: BMC 2021-06-01
Series:Journal of Hematology & Oncology
Subjects:
Envafolimab
PD-L1
dMMR/MSI-H
Subcutaneous injection
Online Access:https://doi.org/10.1186/s13045-021-01095-1

Internet

https://doi.org/10.1186/s13045-021-01095-1

Similar Items